PODD250117P290000
- 28.60
- 0.000.00%
Insulet Newsroom
Bernstein Maintains Insulet(PODD.US) With Buy Rating, Raises Target Price to $305
BofA Securities Maintains Insulet(PODD.US) With Buy Rating, Announces Target Price $305
Bank of America Securities Keeps Their Buy Rating on Insulet (PODD)
Insulet Is Maintained at Buy by TD Cowen
Insulet Analyst Ratings
TD Cowen Maintains Insulet(PODD.US) With Buy Rating, Maintains Target Price $324
TD Cowen Maintains Insulet(PODD.US) With Buy Rating, Raises Target Price to $324
BTIG Maintains Insulet(PODD.US) With Buy Rating, Raises Target Price to $300
BTIG Raises Price Target on Insulet to $300 From $270, Maintains Buy Rating
Redburn Atlantic Raises Price Target on Insulet to $300 From $270, Keeps Buy Rating
Insulet Is Maintained at Overweight by JP Morgan
Insulet Analyst Ratings
J.P. Morgan Maintains Insulet(PODD.US) With Buy Rating, Raises Target Price to $330
Morgan Stanley Maintains Insulet(PODD.US) With Buy Rating, Maintains Target Price $317
Insulet's Strong International Performance and Optimistic Type 2 Diabetes Market Outlook Drive Positive Analyst Rating
Citigroup Raises Price Target on Insulet to $310 From $283, Keeps Buy Rating
Insulet Is Maintained at Overweight by Wells Fargo
Insulet Analyst Ratings
Citi Maintains Insulet(PODD.US) With Buy Rating, Raises Target Price to $310
Wells Fargo Maintains Insulet(PODD.US) With Buy Rating, Raises Target Price to $305